3/5Nuo Therapeutics, Inc. (AURX): Going-concern doubt

Market data

Price before filing: $0.83 (2026-08-13 close, split/dividend-adjusted)
Market cap at flag: $37.3M (2026-08-14) · Latest: $62.9M (2026-10-15)

What happened next

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Insider trading around this filing

90 days before the flag: no open-market insider sales or purchases reported.
30 days after: 1 insider bought $10K (2 purchases)

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-05-16 to 2026-09-13. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

Verified excerpt

"As such, we believe that substantial doubt about our ability to continue as a going concern exists."

Quoted from the filing. Source

What this means

The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.

Source: management disclosure in Form 10-Q (period 2026-06-30)

Why this score: quarterly (unaudited) disclosure